Second Biomarker Expert Meeting in Heidelberg
News Apr 28, 2010
Numerous experts in molecular diagnostics convened at the Second Workshop of the Biomarker Discovery Center in Heidelberg. More than 40 researchers from universities, hospitals and industry from various regions of Germany made their way to the city despite adverse travel conditions caused by the volcanic ash cloud.
The BDC collaborates with clinical and scientific institutions to identify candidate molecular biomarkers using the latest technologies and investigates their potential role in various diseases including cancers and cardiovascular conditions as well as veterinary indications.
Peer Stahler, CSO of febit, the provider of the technology used for the analysis of novel biomarkers at the BDC, inaugurated the Second BDC Workshop.
“More than 200 candidate biomarkers for 14 different diseases were identified in pilot studies at the BDC during its first year,” said Peer Staehler in his introductory presentation. “This demonstrates the tremendous progress made by the research conducted there. Some studies have been published, and others have been submitted for publication in high-ranking journals.”
In his keynote lecture, Prof. Dr. med. Hugo A. Katus, medical director at the Heidelberg University Hospital, gave an overview of the two-decade history of troponin diagnostics in myocardial infarction.
“It is an arduous path to the establishment of a novel biomarker for routine diagnostics,” said Dr. Katus. “But with tenacity and cutting-edge scientific research, medicine may benefit from considerably improved diagnostics and thus provide the patients with more targeted therapies.”
Dr. Armin Pscherer from the Biotech Cluster Rhine-Neckar explained, “The BioRN Cluster Management appreciates the joint development of febit and the BDC. febit is a pioneer for biomarker discovery and the BDC is an essential component of the BioRN excellence cluster focussing on personalized medicine.”
Subsequently, the latest research results obtained in BMBF-supported projects at the BDC were presented and discussed. The first session dealt with DNA-based markers that were identified using latest-generation sequencing technologies and febit´s dedicated HybSelect technology for selective enrichment of target DNA fragments. RNA-based markers were presented in the second session, focussing on microRNAs with regulatory functions that may be impaired in various diseases. MicroRNAs were identified as highly specific markers in the recent past – using febit´s microRNA profiling technology, specific microRNA signatures were found to be clearly associated with a number of different malignancies.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Blood Test Rapidly Detects Signs of Pancreatic CancerNews
The new test can rapidly screen a drop of blood for biomarkers of pancreatic cancer, and provide results in less than an hour.READ MORE
Comments | 0 ADD COMMENT
Epigenetics in the nervous system: development and disease
Oct 01 - Oct 03, 2018